查看购物车
  • Traditional Chinese
  • English
2030 年中东和非洲传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路
市场调查报告书
商品编码
1562243

2030 年中东和非洲传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路

Middle East & Africa Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 93 Pages | 订单完成后即时交付

价格

2022年中东和非洲传染病治疗市场价值为57.2281亿美元，预计到2030年将达到72.3761亿美元；预计2022年至2030年复合年增长率为3.0%。

传染病发生率上升推动中东和非洲传染病治疗市场

传染病是由病毒、寄生虫、细菌、真菌、有毒产物和其他传染源引起的。爱滋病毒是全世界的重大公共卫生议题。根据联合国爱滋病毒/爱滋病联合规划署 (UNAIDS) 的数据，2020 年，约有 3,770 万人感染爱滋病毒。其中，3600万是成年人，170万是0-14岁的儿童。此外，超过一半（53%）是女孩和妇女。此外，2020 年全球报告了 150 万新的爱滋病毒病例。同样，肝炎是由病毒感染引起的肝臟感染。肝炎病毒的主要类型为甲型、乙型、丙型、丁型和戊型 根据世界卫生组织(WHO) 统计，全球约有5,800 万人患有慢性丙型肝炎病毒感染，每年约有150 万人患有慢性丙型肝炎病毒感染。

据世界卫生组织称，结核病 (TB) 是全球第 13 大死亡原因，也是仅次于 COVID-19 的第二大传染病。 2020 年，结核病导致 150 万人死亡（其中 214,000 人感染爱滋病毒）。此外，2020年全球有1,000万人患有结核病，其中包括110万名儿童、330万名女性和560万男性。此外，医院获得性感染或医疗保健相关感染（HAI）的发生率和死亡率很高。此外，每年医疗保健系统的支出也是巨大的。因此，全球传染病率的上升推动了传染病治疗市场的成长。

中东和非洲传染病治疗市场概述

中东和非洲的传染病治疗市场包括对阿联酋、沙乌地阿拉伯、南非以及中东和非洲其他地区的国家级分析。市场的成长可归因于慢性病毒性疾病的流行以及该地区不断增长的研究。此外，先进医疗设施的出现可能会在预测期内推动市场成长。由于庞大的人口基数和日益流行的传染病，沙乌地阿拉伯是中东和非洲成长最快的地区之一。沙乌地阿拉伯的结核病是透过移民工人和朝圣者传播。根据世界资料图谱，沙乌地阿拉伯的结核病发生率从2002年的每10万人17例逐渐下降到2021年的每10万人8例。 ），在沙乌地阿拉伯，控制血液和呼吸道非常具有挑战性。据世界卫生组织称，流感和肺炎死亡人数占全国总死亡人数的4.58%。为了应对不断增长的流感病例，沙乌地阿拉伯公共卫生实验室满足了世界卫生组织被认可为沙乌地阿拉伯国家流感中心的所有要求。该中心在快速检测和监测传染病方面发挥关键作用。 NIAID 积极参与该地区传染性病毒疾病的研究，包括中东呼吸道症候群冠状病毒 (MERS-CoV)。 MERS-CoV 是一种新发现的冠状病毒，已传播到该地区至少九个国家。 NIAID 积极参与该地区传染性病毒性疾病的研究。同样，该地区的产品推出也在增加，并对患者的生活品质产生积极影响。因此，预计越来越多的病毒性疾病和产品上市将推动该国传染病治疗的成长。

中东和非洲传染病治疗市场收入及 2030 年预测（百万美元）

中东和非洲传染病治疗市场细分

中东和非洲传染病治疗市场按药物类别、适应症、给药途径、配销通路和国家分类。

依药物类别，中东和非洲传染病治疗市场分为抗病毒、抗菌、抗真菌等。 2022 年，抗病毒药物领域占据最大的市场份额。

从适应症来看，中东和非洲传染病治疗市场分为爱滋病毒、肝炎、结核病、流感、HPV等。 2022 年，HIV 占据最大的市场份额。

根据给药途径，中东和非洲传染病治疗市场分为口服、肠胃外、外用等。 2022 年，口腔细分市场占据最大的市场份额。

从配销通路来看，中东和非洲传染病治疗市场分为医院药局、零售药局等。 2022年，医院药局占最大的市场份额。

按国家/地区划分，中东和非洲传染病治疗市场分为沙乌地阿拉伯、南非、阿联酋以及中东和非洲其他地区。 2022 年，沙乌地阿拉伯在中东和非洲传染病治疗市场份额中占据主导地位。

艾伯维公司、安斯泰来製药公司、拜耳公司、罗氏公司、吉利德科学公司、葛兰素史克公司、默克公司和辉瑞公司是中东和非洲传染病治疗市场上的一些领导公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：中东和非洲传染病治疗市场 - 主要市场动态

  • 中东和非洲传染病治疗市场 - 主要市场动态
  • 市场驱动因素
    • 传染病病率上升
    • 越来越关注传染病治疗的经费与研发
  • 市场限制
    • 抗感染药物抗药性的出现及相关副作用
  • 市场机会
    • 抗生素抗药性威胁不断升级
  • 未来趋势
    • 产品批准和发布数量不断增加
  • 驱动因素和限制的影响：

第 5 章：传染病治疗市场 - 中东和非洲市场分析

  • 中东和非洲传染病治疗市场收入，2022-2030

第 6 章：中东和非洲传染病治疗市场分析 - 按药物类别

  • 概述
  • 抗病毒剂
  • 抗菌
  • 抗真菌
  • 其他的

第 7 章：中东和非洲传染病治疗市场分析 - 按适应症

  • 概述
  • 爱滋病
  • 肝炎
  • 结核
  • 流感
  • HPV病毒
  • 其他的

第 8 章：中东和非洲传染病治疗市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 专题
  • 其他的

第 9 章：中东和非洲传染病治疗市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：中东和非洲传染病治疗市场 - 国家分析

  • 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 中东和非洲其他地区

第 11 章：传染病治疗市场-产业格局

  • 概述
  • 传染病治疗市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 12 章：公司简介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附录

Product Code: BMIRE00030459

The Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is expected to reach US$ 7,237.61 million by 2030; it is estimated to register a CAGR of 3.0% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

Middle East & Africa Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims. According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases. NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.

Middle East & Africa Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Infectious Disease Therapeutics Market Segmentation

The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the Middle East & Africa infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Middle East & Africa Market Analysis

  • 5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Middle East & Africa Infectious Disease Therapeutics Market
    • 10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bayer AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 GSK Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AbbVie Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Merck & Co Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Astellas Pharma Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation
  • Table 2. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 21. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 22. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 24. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Middle East & Africa Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Growth Strategies in the Infectious Disease Therapeutics Market